FAM66E
Putative protein FAM66E
Also known as: FA66E_HUMAN
Protein identityUniProt · HPA
OverviewNCBI Gene
No narrative summary is available for FAM66E in this catalog release; identity and structured annotations are shown without generated factual claims.
Canonical amino-acid sequenceUniProt
47 residues, UniProt reviewed canonical sequence.
>P0C841|FAM66E
1 MLASGAESQD RYRNTPSSRI FTPGFRPTPA TTPEPGIYMF NMEPSQPLocalizationUniProt · AlphaFold · HPA
Whether an antibody against FAM66E can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.
- Antibody reachability
- Unknown
- Secreted
- No
- Transmembrane segments
- 0
- Mean surface accessibility (rSASA)
- 0.62
Cancer expressionTCGA
Across TCGA tumor cohorts, this protein is over-expressed in roughly 4% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).
Antibody and autoantibody relevanceSeroatlas analysis
Seroatlas reads FAM66E as an antibody target. Whether an autoantibody or antibody against FAM66E could matter depends on whether native FAM66E is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.
FAM66E is annotated as predominantly intracellular. Intracellular proteins are common autoantibody markers, becoming visible to the immune system after cell injury or altered processing, but are usually markers of disease rather than direct drivers.
Annotation status
The present source text does not explicitly label FAM66E as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.
Loading the interactive Seroatlas protein explorer...